PomegraStryker Stock Falls 8.8% on Supply Chain Woes
Why is Stryker stock down today?
Stryker (SYK) stock fell 8.81% to $276.43 on Tuesday after the medical device maker said supply and manufacturing problems in its peripheral vascular and joint-replacement units would persist into the fourth quarter.
Key numbers
| Stock price | $276.43-8.81% |
|---|---|
| Market cap | $106.03B |
| YTD performance | -21% |
| 2026 organic growth guidance | 8.3%-9.3%maintained |
| Peripheral vascular growth drag | 70-80 bps (Q2-Q3) |
| Forward P/E | 18.91x |
What happened
Stryker (SYK) stock fell 8.81% to $276.43 on Tuesday after the medical device maker said supply and manufacturing problems in its peripheral vascular and joint-replacement units would persist into the fourth quarter. At the Wells Fargo Healthcare Conference, CFO Preston Wells said supply constraints now block full inventory and new business wins in peripheral vascular, pushing the fix from Q3 into Q4. Joint-replacement sales, especially hips, also stayed soft instead of the seasonal rebound Stryker had expected. The stock hit a fresh 52-week low and is down about 21% for the year, though Stryker kept its 2026 growth target of 8.3%-9.3%.
Why it matters
Stryker is one of the world's largest makers of hip and knee implants and vascular devices, so supply problems mean hospitals may face longer waits for its products and Stryker may lose sales to rivals. Its own sales team can't fully restock customers or bid on new peripheral-vascular contracts, which investors read as a deeper problem than a short-term glitch. Because Stryker still backs its full-year target, the reaction shows how sensitive investors are to any sign of delay after a rocky year that included a cyberattack.
Who this affects
- MarketbearishMedium impact
- Medtech investors sell off orthopedic and vascular device stocks broadly.
- CompanybearishHigh impact
- Stryker shareholders see stock hit fresh 52-week low.
- CompetitorsmixedLow impact
- Zimmer Biomet dips in sympathy; Medtronic less exposed.
- IndustryneutralMedium impact
- Highlights ongoing supply-chain fragility in device manufacturing.
Stryker vs Zimmer Biomet, Boston Scientific, Medtronic
How we got here
Cyberattack disrupts Stryker manufacturing and shipping operations
Stryker flags 70-80 bps supply-chain drag on Q2 organic growth
CFO says vascular supply fix pushed to Q4; stock hits 52-week low
What to watch
- Whether peripheral vascular supply constraints ease as targetedQ4 2026
- Joint-replacement and hip demand trends through September2026-09
- Q3 earnings check on 8.3%-9.3% organic growth guidance2026-10
Educational content only. Not investment advice.
More briefsAll briefs →
Strategy Stock Falls 4.4% as Bitcoin Pause Funds STRC Buyback
Strategy (MSTR), formerly MicroStrategy, skipped bitcoin buys to repurchase $176M of STRC preferred shares.
Intel Stock Jumps 9% on Report of 10% CPU Price Hike
AMD Stock Jumps 6% on $2 Trillion AI Market Forecast
Advanced Micro Devices (AMD) shares rose 6% to $506 after raising its 2030 AI market forecast to $2 trillion.